ADGRE2

Across TCGA pan-cancer cohorts, ADGRE2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADGRE2 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADGRE2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ADGRE2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

UCEC, LUSC, and PRAD are the cancer types where ADGRE2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.961	0.618	.015	16	view →
LUSC	OS	Median	III,IV	0.192	0.689	.003	12	view →
PRAD	DFS	Median	All	0.770	0.934	.008	6	view →
ACC	DFS	Median	All	0.112	0.544	.042	3	view →
SCLC	DFS	Median	All	1.000	0.465	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADGRE2–UCEC (DFS)

Open the UCEC breakdown →